Cited by 173Retinal Development and DisordersRetinal Diseases and TreatmentsVirus-based gene therapy research

Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives

Open access
Garafalo, Alexandra V., Cideciyan, Artur V., Héon, Elise, Sheplock, Rebecca, Pearson, Alexander, WeiYang Yu, Caberry, Sumaroka, Alexander, Aguirre, Gustavo D. +1 more·2020·Progress in Retinal and Eye Research

Abstract

Due to improved phenotyping and genetic characterization, the field of 'incurable' and 'blinding' inherited retinal diseases (IRDs) has moved substantially forward. Decades of ascertainment of IRD patient data from Philadelphia and Toronto centers illustrate the progress from Mendelian genetic types to molecular diagnoses. Molecular genetics have been used not only to clarify diagnoses and to direct counseling but also to enable the first clinical trials of gene-based treatment in these diseases. An overview of the recent reports of gene augmentation clinical trials by subretinal injections is used to reflect on the reasons why there has been limited success in this early venture into therapy. These first-in human experiences have taught that there is a need for advancing the techniques of delivery of the gene products - not only for refining further subretinal trials, but also for evaluating intravitreal delivery. Candidate IRDs for intravitreal gene delivery are then suggested to illustrate some of the disorders that may be amenable to improvement of remaining central vision with the least photoreceptor trauma. A more detailed understanding of the human IRDs to be considered for therapy and the calculated potential for efficacy should be among the routine prerequisites for initiating a clinical trial.

Integrity signals

Registry

Crossref · 10.1016/j.preteyeres.2019.100827

Cites

235 of 235 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Subfoveal viral gene therapy has been associated with various adverse effects, such as RPE alterations, retinal thinning, foveal morphological changes, vision loss, and variable duration of clinical effects.

    “subfoveal viral gene therapy has been associated with various adverse effects, such as RPE alterations, retinal thinning, foveal morphological changes, vision loss, and the variable duration of clinical effects [281,294,296,297,298].”

Cites

Flagged first, then by citations

12 of the 247 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G.
Affiliations
  • University of Pennsylvania (US)
  • University of Toronto (CA)
Corresponding author
Jacobson, Samuel G.
Venue
Progress in Retinal and Eye Research
Publisher
Elsevier BV
Published
2020-07
Volume
77
Pages
100827
ISSN
1350-9462 (ISSN-L)
OpenAlex
W2996789825
Cited by
173
References
247
Citations by year
2026: 9 · 2025: 18 · 2024: 17 · 2023: 26 · 2022: 28 · 2021: 48 · 2020: 27
FWCI
2.27
Type
journal article
Language
en
Open access
Locations
  • Progress in Retinal and Eye Research (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health/National Eye Institute (EY-017549)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
inherited retinal disease, subretinal gene therapy, gene augmentation, clinical trials, intravitreal gene delivery, molecular diagnosis, genetic counseling, photoreceptors, retinal degeneration
MeSH terms
Clinical Trials as Topic, Humans, Retinal Degeneration, Retinitis Pigmentosa, Genetic Therapy, Eye Diseases, Hereditary, Gene Transfer Techniques, Leber Congenital Amaurosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review